Menu
close
Please contact us for more information or to learn if you are eligible to participate.
The primary objective of this study is to estimate the safety of the combination of atezolizumab and bevacizumab in patients with advanced/metastatic HCC and Child-Pugh B7 liver dysfunction by grade 3-5 adverse event rate.
Principal Investigator | Lee Drinkard, MD |
Sponsor | Novocure |
Type of Trial | Interventional |